Drugs / adipose-derived adult mesenchymal stem cells
adipose-derived adult mesenchymal stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05520086 | Nov 2022 → Jun 2024 | Lyell syndrome, Stevens-Johnson syndrome, chronic conjunctivitis, pemphigoid | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adipose-derived adult mesenchymal stem cells | “The investigational drug consists of locally administered, expanded, allogeneic adipose-derived adult mesenchymal stem cells (ASCs), at a dose of 5 million cells per ml (0,5 ml...” NCT05520086 ↗ |
| Known as | ASC | “Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis” NCT05520086 ↗ |
| Known as | ASCs | “allogeneic adipose-derived adult mesenchymal stem cells (ASCs)” NCT05520086 ↗ |
| Known as | MSC | “Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells” NCT05520086 ↗ |
| Modality | Cell therapy | “allogeneic adipose-derived adult mesenchymal stem cells (ASCs)” NCT05520086 ↗ |
| Route | Other | “by subcnjunctival injection and topical conjunctival injection” NCT05520086 ↗ |